What Happened?
New York, NY-based Vascular-Biogenics-Limited-Therapeutics Appointed Sam Backenroth as Chief Financial Officer
About the Company
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.
About the Person
Sam Backenroth is Chief Financial Officer at Vascular Biogenics Limited Therapeutics. Previously, Sam held various senior HR leadership roles in the industry.
Info Source
News
Short Profile